Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, andRecent Innovations

The second-generation lipid-based nanocarrier system, nanostructured lipid carriers (NLCs), has received much attention due to their distinct properties that enable them to address the various limitations that afflict both solid lipid nanoparticles and the conventional delivery system. The special structure (solid lipids/liquid lipids blend) of NLCs provides a better encapsulation, stability, controlled release, and biocompatibility of drugs, therefore, leading to the effective transportation of hydrophilic and lipophilic drugs. This review briefly examines the design methods, formulation strategies, and other more sophisticated characterization methods, such as traditional characterization (e.g., dynamic light scattering (DLS) and X-ray diffraction) and new methods (e.g., cryo-EM and small-angle X-ray scattering (SAXS) that provide an effect on particle size, lipid crystallinity, and release kinetics. The review notes Process Analytical Technology (PAT) and its ability to aid the real-time monitoring and scale-up production of NLC products. Recent dosage forms that have been used as therapeutic agents that involve the use of NLCs are critically discussed, such as the following routes of administration: oral, transdermal, nasal, ocular, pulmonary, and targeted delivery. Moreover, we will review how NLCs can serve to improve bioavailability, enhance patient compliance, and provide sitespecific action of drug delivery. A recent analysis of patents is reviewed to identify where innovative space is being created regarding surface functionalization, hybrid systems, and combinatorial therapies, as well as the challenges faced, such as regulatory implications and translational opportunities. This work provides a summary of the formulation science, characterization methods, and patent data to offer an overview of the current state and prospective future work of NLCs with respect to drug targeting, delivery, and the nanomedicine field.

Authors

Institutions

Publication Details

Journal
Current Pharmaceutical Design
Published
2026-06-30
DOI
https://doi.org/10.2174/0113816128411459260217142345
Primary Topic
Advancements in Transdermal Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, andRecent Innovations

Muhammad Salim Khan, J Ali, Rabea Parveen, Rabnoor Alam et al.
Current Pharmaceutical Design
Advancements in Transdermal Drug Delivery
article

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, andRecent Innovations

Muhammad Salim Khan, J Ali, Rabea Parveen, Rabnoor Alam, Nida Nehal, Devika Unnithan, Harshita Singh, Ajay Pratap Singh Chauhan, V V Siva Krishna Pushadapu, Divya Vohora
article en

Abstract

The second-generation lipid-based nanocarrier system, nanostructured lipid carriers (NLCs), has received much attention due to their distinct properties that enable them to address the various limitations that afflict both solid lipid nanoparticles and the conventional delivery system. The special structure (solid lipids/liquid lipids blend) of NLCs provides a better encapsulation, stability, controlled release, and biocompatibility of drugs, therefore, leading to the effective transportation of hydrophilic and lipophilic drugs. This review briefly examines the design methods, formulation strategies, and other more sophisticated characterization methods, such as traditional characterization (e.g., dynamic light scattering (DLS) and X-ray diffraction) and new methods (e.g., cryo-EM and small-angle X-ray scattering (SAXS) that provide an effect on particle size, lipid crystallinity, and release kinetics. The review notes Process Analytical Technology (PAT) and its ability to aid the real-time monitoring and scale-up production of NLC products. Recent dosage forms that have been used as therapeutic agents that involve the use of NLCs are critically discussed, such as the following routes of administration: oral, transdermal, nasal, ocular, pulmonary, and targeted delivery. Moreover, we will review how NLCs can serve to improve bioavailability, enhance patient compliance, and provide sitespecific action of drug delivery. A recent analysis of patents is reviewed to identify where innovative space is being created regarding surface functionalization, hybrid systems, and combinatorial therapies, as well as the challenges faced, such as regulatory implications and translational opportunities. This work provides a summary of the formulation science, characterization methods, and patent data to offer an overview of the current state and prospective future work of NLCs with respect to drug targeting, delivery, and the nanomedicine field.

Current Pharmaceutical DesignVol. 32
Vignan's Foundation for Science, Technology & Research (IN), Jamia Hamdard (IN)
Openalex Percentile: Top 9%
Advancements in Transdermal Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.